Exelixis Gets FDA Approval For Its CABOMETYX Tablets By: Benzinga via Benzinga April 25, 2016 at 14:52 PM EDT Exelixis, Inc. (NASDAQ: EXEL) revealed the FDA has given its approval for its CABOMETYX (cabozantinib) tablets for the treatment of ... Read More >> Related Stocks: Exelixis Inc